Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
UCB | Brussels | EUR | Real-time | |
UCBb | BATS Europe | EUR | Delayed | |
UCBJY | OTC Markets | USD | Delayed | |
0NZT | London | EUR | Real-time | |
UCB | TradeGate | EUR | Delayed | |
UCB | Frankfurt | EUR | Delayed | |
UCB | Vienna | EUR | Real-time |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; minzasolmin and UCB0222 for Parkinson’s disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Name | Age | Since | Title |
---|---|---|---|
Jonathan M. Peacock | 65 | 2021 | Independent Chair of the Board |
Jan Berger | 67 | 2019 | Independent Director |
Jean-Christophe Tellier | 65 | 2014 | CEO & Executive Director |
Susan Gasser | 69 | 2021 | Independent Director |
Cyril Janssen | 53 | 2015 | Director |
Charles-Antoine Emmanuel T. Janssen | 53 | 2012 | Director |
Ulf Arne Wiinberg | 66 | 2016 | Independent Director |
Pierre L. Gurdjian | 63 | 2016 | Independent Director |
Jonkheer Cédric van Rijckevorsel | 54 | 2014 | Director |
Gerhard N. Mayr | 78 | 2005 | Honorary Chairman |
Georges Jacobs de Hagen | 84 | 2005 | Honorary Chairman |
Diégo du Monceau de Bergendal | 74 | 1984 | Honorary Chairman |
Mark Eyskens | - | 2005 | Honorary Chairman |
Dame Kay Davies | 73 | 2014 | Independent Director |
Maelys Castella | 58 | 2023 | Independent Director |
Guy Keutgen | - | 1990 | Honorary Director |
Jean-Louis Vanherweghem | - | - | Honorary Director |
Gaëtan van de Werve | - | 2006 | Honorary Director |
Jean-Pierre Kinet | 71 | 2008 | Honorary Director |
Alice Dautry | 74 | 2015 | Honorary Director |
Prince Lorenz | - | 2001 | Honorary Director |
Peter J. Fellner | 81 | 2005 | Honorary Director |
Alan John Blinken | - | - | Honorary Director |
Frederic Roch Doliveux | 68 | 2005 | Honorary Director |
Arnoud de Pret Roose de Calesberg | 80 | 2005 | Honorary Director |
Norman J. Ornstein | 76 | 2008 | Honorary Director |
Thomas Fulton Wilson McKillop | 81 | 2009 | Honorary Director |
Jean van Rijckevorsel | - | 1992 | Honorary Director |
Rodolfo J. Savitzky | 62 | 2024 | Independent Director |
Dolca Thomas | 54 | 2024 | Independent Director |
Nefertiti Greene | 53 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review